LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2006--NitroMed Inc. (NASDAQ: NTMD) today announced that it will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference, being held February 7 - 9 at the Grand Hyatt New York. Michael D. Loberg, Ph.D., NitroMed’s President and Chief Executive Officer, will present a corporate overview and progress report on the commercial launch of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) on Wednesday, February 8, at 11:00 a.m. (ET).
